Patent ID: 7511070

Claim:
A therapeutic method for treating osteoporosis comprising administering to a mammal in need of such therapy, an effective amount of a compound of formula VI: wherein R 6 is (C 1 -C 6 )alkyl, or aryl, optionally substituted by 1, 2, or 3 V; R 7 is phenyl, optionally substituted by 1, 2, or 3 V; or R 7 is (C 1 -C 12 )alkyl, halo(C 1 -C 12 )alkyl, (C 3 -C 6 )cycloalkenyl, or (C 1 -C 6 )alkyl(C 3 -C 6 )cycloalkenyl; R 8 is hydrogen or phenyl, optionally substituted at the 2-position with R j , and optionally substituted by 1, 2, or 3 V; R 9 is hydrogen, halo, aryl, aryl(C 1 -C 3 )alkyl, heteroaryl(C 1 -C 3 )alkyl, halo(C 1 -C 12 )alkyl, (C 1 -C 12 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkylcyclo(C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkenyl, or (C 1 -C 6 )alkyl(C 3 -C 6 )cycloalkenyl, wherein any aryl or heteroaryl may optionally be substituted by 1, 2, or 3, V; or R 9 and R j together are â€”CH 2 CH 2 â€”, â€”Sâ€”, â€”Oâ€”, â€”N(H)â€”, â€”N[(C 1 -C 6 )alkyl]-, or â€”CHâ•CHâ€”; â€” is a single bond or is â€”C(B)(D)â€”, wherein B and D are each independently hydrogen, (C 1 -C 6 )alkyl, or halo; V is OPO 3 H 2 , (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, mercapto, (C 1 -C 4 )alkylthio, halo, trifluoromethyl, pentafluoroethyl, nitro, N(R n )(R o ), cyano, trifluoromethoxy, pentafluoroethoxy, benzoyl, hydroxy, â€”(CH 2 ) 0-4 C(â•O)(C 1 -C 6 )alkyl, â€”UC(â•O)(C 1 -C 6 )alkyl, benzyl, â€”OSO(CH 2 ) 0-4 CH 3 , â€”U(CH 2 ) 0-4 COOR p , â€”(CH 2 ) 0-4 COOR p , â€”U(CH 2 ) 0-4 OR p , â€”U(CH 2 ) 1-4 C(â•O)R k , â€”(CH 2 ) 0-4 C(â•O)R k , â€”U(CH 2 ) 1-4 R k â€”, â€”(CH 2 ) 0-4 R k , or â€”U(CH 2 ) 2-4 OC(â•O)R p ; wherein U is O, N(R m ), or S; Z is â€”(CH 2 ) 1-3 â€”, or a covalent bond; R k is amino, optionally substituted with one or two (C 1 -C 6 )alkyl; or an N-heterocyclic ring optionally containing 1 or 2 additional N(R 1 ), S, or nonperoxide O, wherein R) is H(C 1 -C 6 )alkyl, phenyl, or benzyl; R n and R o are independently hydrogen, (C 1 -C 6 )alkyl, phenyl, benzyl, or (C 1 -C 6 )alkanoyl; or R n and R o together with the nitrogen to which they are attached are a 3, 4, 5, or 6 membered heterocyclic ring; R p is H or (C 1 -C 6 )alkyl; and R m and R q are independently hydrogen, (C 1 -C 6 )alkyl, phenyl, benzyl, or (C 1 -C 6 )alkanoyl; or a pharmaceutically acceptable salt thereof; provided that at least one of R 6 , R 7 , R 8 , and R 9 is substituted with at least one V; provided that at least one of R 6 and R 8 is unsubstituted; provided that R 9 is not methyl, ethyl, chloro, or bromo when Z is a covalent bond; and provided that Z is not â€”CH 2 â€” when R 6 is phenyl, substituted only at the 4-position with â€”O(CH 2 ) 1-3 R k wherein R k is pyrrolidino, piperidino, 4-morpholino, dimethylamino, diethylamino, or hexamethyleneimino; and provided that R 9 is not 2-chloroethyl when Z is a covalent bond; and R 6 is phenyl, substituted only at the 4-position with â€”O(CH 2 ) 2 OH.